AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism
Stephen L. Pinkosky(Esperion Therapeutics (United States)), Roger S. Newton(Medical Protective)
Cited by 234
Related Papers
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
|Nature Communications|2016|475
ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
|Journal of Lipid Research|2013|87